Supplemental methods

Patients and DCOG ALL-10 protocol
All patients received eight doses of native E.coli asparaginase (5,000 IU/m 2 , every three days) in induction. In the MR group, PEGasparaginase (2,500 IU/m 2 , every other week) was
given during the first 30 weeks of the intensification/reinduction course. In case of an allergy to PEGasparaginase, the patient was switched to Erwinia asparaginase (20,000 IU/m 2 , per dose) 2-3 times per week to complete 30 weeks of Erwinia asparaginase therapy.
(1) All asparaginase preparations were administered intravenously.
In the starting phase of our drug monitoring program real-time asparaginase measurements were not available, and patients with silent inactivation were not recognized in time and continued with PEGasparaginase.
Study design and definitions
Serum asparaginase activity trough levels and serum asparaginase antibodies were measured at 15 and 13 different time points for PEGasparaginase and Erwinia asparaginase analysis, respectively.
Allergy was graded according to the National Cancer Institute (NCI) Common
Terminology Criteria for Adverse Events (CTCAE) version 3.0. Silent inactivation was defined as serum PEGasparaginase activity level below 100 U/L at day 7±1 or below 20 U/L at day 14±1
after PEGasparaginase infusion in absence of a clinical allergy. Silent inactivation of Erwinia asparaginase was defined as serum asparaginase activity level below 20 U/L at day 2 after administration of Erwinia asparaginase in absence of a clinical allergy.
Asparaginase activity levels and asparaginase antibodies
Serum asparaginase activity levels were processed and assessed as described earlier. 
Supplemental results
Overview of the patients in trial
Eighty-nine patients were enrolled to monitor PEGasparaginase courses. Twenty patients had clinical allergic reactions to PEGasparaginase. Seven patients showed silent inactivation of PEGasparaginase of which five patients continued with PEGasparaginase, because real-time asparaginase measurements were not available at that moment. The others were switched to Erwinia asparaginase. The remaining 62 patients had no allergy to and silent inactivation of PEGasparaginase.
In another cohort, fifty-nine patients were enrolled to monitor Erwinia asparaginase courses. Only two patients (3%) had an allergy to Erwinia asparaginase, none of patients had silent inactivation of Erwinia asparaginase.
Coli-AAA and PEG-AAA
For comparison, Supplemental Figure 1 shows the Coli-AAA, PEG-AAA and PEGasparaginase activity levels of patients without an allergy and without silent inactivation.
29% of the patients were positive for Coli-AAA before the start of intensification. Also in this group of patients, the Coli-AAA gradually decreased and after five PEGasparaginase infusions, the Coli-AAA levels were below the cut-off. PEG-AAA were absent at the start, gradually increased but remained below the cut-off level. After four doses of PEGasparaginase, the PEG-AAA levels gradually decreased to absent baseline values during therapy. Both asparaginase antibodies did not affect the PEGasparaginase activity levels which remained stable after two
PEGasparaginase infusions until end of therapy, but it should be noted that patients with silent inactivation were removed from this group as well as the patients with clinical allergy (Supplemental Figure 1-C) .
Erwinia-AAA
59 patients were treated to complete 30 weeks of exposure with Erwinia asparaginase 2-3 times per week, after having experienced allergy to or silent inactivation of PEGasparaginase.
The two allergic patients to Erwinia asparaginase were excluded from further analysis, hence 57 remaining patients on Erwinia asparaginase were available for analysis. In Supplemental Figure   2 , the Erwinia-AAA and Erwinia asparaginase activity levels of patients without an allergy to 
